Views & Analysis Immuno-oncology drugs: key to the Cancer Moonshot? Assessing the global challenges inhibiting immuno-oncology market access.
News Keytruda wins another first with approval based on biomarker... For the first time, FDA approves drug on the basis of biomarkers, rather than location.
Views & Analysis The cancer challenge: the quest for a cure is only half the ... The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Views & Analysis Deep Dive: Oncology magazine launched today Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
News With all eyes on IO, Tagrisso could be AZ's ace card AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.
Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
